Skip to main content

Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference

Astria Therapeutics, Inc. (NASDAQ: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th at 9:20am ET.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/oppenheimer33/atxs/2815552. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  216.48
+0.00 (0.00%)
AAPL  262.24
+0.00 (0.00%)
AMD  240.56
+0.00 (0.00%)
BAC  52.04
+0.00 (0.00%)
GOOG  257.02
+0.00 (0.00%)
META  732.17
+0.00 (0.00%)
MSFT  516.79
+0.00 (0.00%)
NVDA  182.64
+0.00 (0.00%)
ORCL  277.18
+0.00 (0.00%)
TSLA  447.43
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.